Baird Downgrades Decibel Therapeutics to Neutral, Lowers Price Target to $5.25
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Jack Allen has downgraded Decibel Therapeutics (NASDAQ:DBTX) from Outperform to Neutral and lowered the price target from $21 to $5.25.
August 10, 2023 | 9:28 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Decibel Therapeutics has been downgraded by Baird from Outperform to Neutral, with a lowered price target from $21 to $5.25.
The downgrade from Outperform to Neutral by Baird, along with a significant reduction in the price target, indicates a less optimistic outlook for Decibel Therapeutics. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100